Recent News

• 01.14.2026 - Biomerica Reports Second Quarter Fiscal 2026 Financial Results
• 12.23.2025 - Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
• 12.11.2025 - Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio
• 11.25.2025 - Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS
• 11.06.2025 - Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
• 10.16.2025 - Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.
• 10.15.2025 - Biomerica Reports First Quarter Fiscal 2026 Financial Results
• 10.08.2025 - Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors

Recent Filings

• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.16.2025 - 8-K Current report
• 10.23.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 10.20.2025 - DEF 14A Other definitive proxy statements
• 10.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.09.2025 - PRE 14A Other preliminary proxy statements